ADC Development for Fallopian Tube Cancer

Over the past years, antibody-drug conjugates (ADCs) have been developed widely for a large number of cancer therapies and are showing unique advantages compared with other traditional therapeutic options. Creative Biolabs offers quality custom ADCs development services against fallopian tube cancer to meet clients’ specific requirements in novel drug development. With years of experience in compound synthesis and antibody development, Creative Biolabs has constructed a solid technical foundation for ADCs design and construction. Our experienced scientists also provide an extensive range of ADCs related products for optimal ADCs preparation.

Introduction of Fallopian Tube Cancer

Fallopian tube cancer or tubal cancer is a type of cancer arising from the fallopian tubes that are a pair of thin tubes that transport a woman's eggs (ova) from her ovaries (where they are housed) to her uterus (aka "womb"). Normally, cells growth is highly regulated in the body. If the cells grow out of control, tumors will occur abnormally. Fallopian tube cancer is an uncontrolled growth of malignant cells in woman's fallopian tubes. Most of fallopian tube cancers are papillary serous adenocarcinomas. Symptoms of tubal cancer often include vaginal bleeding, vaginal discharge, abdominal pain and pelvic pain. Currently, the specific cause of cancer is unknown. Some risk factors will lead to such disease, including a history of chronic infection and/or inflammation, a family history of the fallopian tube or ovarian cancer, gene mutations particularly the BRCA1 gene. Treatments for the cancer consist of surgery, chemotherapy, targeted therapy, radiation therapy and hormone therapy.

Definitions of fallopian tube cancer stage. Fig.1 Definitions of fallopian tube cancer stage.

Current Therapeutic Strategies for Fallopian Tube Cancer

Treatment options for fallopian tube cancer depend on the type and stage of cancer, possible side effects, and the patient’s preferences and overall health. Some traditional treatment strategies include salpingo-oophorectomy, hysterectomy, lymphadenectomy/lymph node dissection, omentectomy, cytoreductive/debulking surgery, chemotherapy and radiation therapy. However, these therapeutic methods often present all kinds of side effects such as causing short-term pain, difficulty with concentration and memory.

Thus, some new therapies have been designed. Targeted therapy is a novel treatment way targeting cancer’s specific genes, proteins, or the tissue environment, such as the PARP inhibitors target the BRCA genes and anti-angiogenesis inhibitors target the vascular endothelial growth factor (VEGF). Besides, hormone therapy is used to treat relapsed low-grade fallopian tube cancer, including tamoxifen (Novladex) and aromatase inhibitors, such as letrozole (Femara), anastrozole (Arimidex), and exemestane (Aromasin).

ADCs are another form of targeted immunotherapy developed for the treatment of fallopian tube cancer. Sofituzumab vedotin (RG7458 or DMUC5754A) is an ADC composed of an anti-MUC16 monoclonal antibody and potent anti-mitotic agent, monomethyl auristatin E (MMAE). Preclinical and clinical trial results showed that sofituzumab vedotin has potent antitumor activity in MUC16-positive tumor with favorable safety profile.

Structure of sofituzumab vedotin. Fig.2 Structure of sofituzumab vedotin. (Abdollahpour-Alitappeh, 2018)

Target of ADC development for fallopian tube cancer:

Based on years of experience on ntibody production and bioconjugation, Creative Biolabs offers a full range of ADCs development services targeting the fallopian tube cancer. We believe our established platform will deliver high quality services and products that suit your research objectives, budget and timeline requirement. To discuss your unique ADCs preparation service demands or to request a proposal, please contact us.

Reference

  1. Abdollahpour-Alitappeh, M.; et al. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line. Artificial cells, nanomedicine, and biotechnology. 2018, 46: 1-8.


Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
 Tel: 44-207-097-1828
 Email:

Inquiry

Top